Tysinor 500 - Tablet Capecitabine - 500mg 1 Tablet(s) / Tablet Genvio Pharma Ltd. Introduction: Tysinor 500 is used in the treatment of cancer of breast, colon, and rectum. It may be also used to treat other conditions, as determined by the doctor. It is used alone or in combination with some other medicine as a part of chemotherapy. Tysinor 500 should be taken with food within 30 minutes after eating a meal. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has... Uses of Tysinor 500: Breast cancerCancer of colon and rectum Side effects of Tysinor 500: VomitingWeaknessNauseaAbdominal painDiarrheaBlisters on fingers/feet How to use Tysinor 500: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tysinor 500 is to be taken with food. How Tysinor 500 works: Tysinor 500 is an anticancer medication. Inside the body, this medicine gets converted into 5-fluorouracil (chemical). This chemical hampers the synthesis of genetic materials (RNA and DNA) in the cancer cells, thereby interferes with their growth. This slows down the growth of cancer cells and eventually kills them. Indication: Breast cancer, Colorectal cancer, Gastric cancer, Oesophageal cancer Administration: Swallow with water within 30 min after a meal Adult Dose: Oral Breast cancer; Colorectal cancer Adult: 1.25 g/m2 bid for 2 wk followed by a 1 wk rest period; therapy to be given in 3-wk cycles. Recommended treatment duration for colorectal cancer: 6 mth. May be used in combination with docetaxel at 75 mg/m2, given as a 1-hr IV infusion once every 3 wk for the treatment of breast cancer. Gastric cancer Adult: Used in combination with a platinum-based compound, 1 g/m2 bid for 14 days, followed by a 7-day rest period. 1st dose is given on the evening of day 1 and the last dose on the morning of... Renal Dose: Renal impairment: CrCl (ml/min) 51-80 No adjustment needed. 30-50 Reduce dose to 950 mg/m2 bid when starting dose is 1.25 g/m2 bid. No dose adjustment is needed when starting dose is 1 g/m2. <30 Avoid use. Contraindication: History of severe and unexpected reactions to fluoropyrimidine therapy; severe renal impairment; pregnancy, lactation. Hypersensitivity. Mode of Action: Capecitabine is a prodrug that is converted to fluorouracil following oral administration, which in turn inhibits thymidylate synthetase, blocking the methylation of deoxyuridylic acid to thymidylic acid, interfering with DNA, and to a lesser degree, RNA synthesis. Precaution: Hepatic dysfunction, bone marrow suppression, poor nutritional status, warfarin therapy. Child, elderly, prior extensive pelvic radiation or alkylating therapy. Moderate renal impairment; CBC with differential; monitor hepatic and renal function. Discontinue use if intractable diarrhoea, stomatitis, bone marrow suppression or MI develops. Side Effect: 10% Diarrhea,Nausea,Anemia,Lymphopenia,Hand and foot syndrome,Edema,Fatigue,Fever,Headache,Pain,Paresthesia,Alopecia,Dermatitis,Abdominal pain,Anorexia,Appetite decreased,Constipation,Dyspepsia,Stomatitis,Vomiting,Neutropenia,Thrombocytopenia,Dyspnea,Bilirubin increased,Eye irritation 1-10% Chest pain,Dermatitis,Pruritus,Rash,Dizziness,Headache,Weakness,Dehydration,Dry mouth,Dyspepsia,Taste disturbance,Back pain Potentially Fatal: Cardiotoxicity, bone-marrow depression and hyperbilirubinaemia. Pregnancy Category Note: Pregnancy Category: C Lactation: excretion in milk unknown; use with caution Interaction: Antacids containing aluminum and magnesium, leucovorin, anticoagulants, phenytoin, allopurinol.